These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 34000978)
1. Intracellular ROS profile in hematopoietic progenitors of MDS patients: association with blast count and iron overload. Chan LSA; Gu LC; Leitch HA; Wells RA Hematology; 2021 Dec; 26(1):88-95. PubMed ID: 34000978 [No Abstract] [Full Text] [Related]
2. Impact of iron overload by transfusion on survival and leukemia transformation of myelodysplastic syndromes in a single center of China. Wang Y; Huang L; Hua Y; Liu H; Jiang H; Wang H; Zhang W; Fu R; Shao Z Hematology; 2021 Dec; 26(1):874-880. PubMed ID: 34753406 [TBL] [Abstract][Full Text] [Related]
3. Iron overload may promote alteration of NK cells and hematopoietic stem/progenitor cells by JNK and P38 pathway in myelodysplastic syndromes. Hua Y; Wang C; Jiang H; Wang Y; Liu C; Li L; Liu H; Shao Z; Fu R Int J Hematol; 2017 Aug; 106(2):248-257. PubMed ID: 28405919 [TBL] [Abstract][Full Text] [Related]
4. CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes. Abe-Suzuki S; Kurata M; Abe S; Onishi I; Kirimura S; Nashimoto M; Murayama T; Hidaka M; Kitagawa M Lab Invest; 2014 Nov; 94(11):1212-23. PubMed ID: 25199050 [TBL] [Abstract][Full Text] [Related]
5. Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia. Chaudhary AK; Chaudhary S; Ghosh K; Shanmukaiah C; Nadkarni AH Asian Pac J Cancer Prev; 2016; 17(3):1519-29. PubMed ID: 27039800 [TBL] [Abstract][Full Text] [Related]
6. Selective blast cell reduction in elderly patients with acute myeloid leukemia secondary to myelodysplastic syndrome treated with methylprednisolone. Suzuki K; Ohishi K; Sekine T; Masuya M; Katayama N Int J Hematol; 2007 May; 85(4):344-9. PubMed ID: 17483080 [TBL] [Abstract][Full Text] [Related]
7. Iron overload impairs normal hematopoietic stem and progenitor cells through reactive oxygen species and shortens survival in myelodysplastic syndrome mice. Jin X; He X; Cao X; Xu P; Xing Y; Sui S; Wang L; Meng J; Lu W; Cui R; Ni H; Zhao M Haematologica; 2018 Oct; 103(10):1627-1634. PubMed ID: 29903757 [TBL] [Abstract][Full Text] [Related]
8. Clinical and biological characteristics of acute myeloid leukemia with 20-29% blasts: a retrospective single-center study. Mei C; Ren Y; Zhou X; Ye L; Ma L; Luo Y; Lin P; Xu W; Lu C; Yang H; Yu W; Mao L; Wei J; Jin J; Tong H Leuk Lymphoma; 2019 May; 60(5):1136-1145. PubMed ID: 30301399 [TBL] [Abstract][Full Text] [Related]
9. Increased CD34+CD38 -CD123 + cells in myelodysplastic syndrome displaying malignant features similar to those in AML. Li LJ; Tao JL; Fu R; Wang HQ; Jiang HJ; Yue LZ; Zhang W; Liu H; Shao ZH Int J Hematol; 2014 Jul; 100(1):60-9. PubMed ID: 24846193 [TBL] [Abstract][Full Text] [Related]
10. The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine. Miltiades P; Lamprianidou E; Vassilakopoulos TP; Papageorgiou SG; Galanopoulos AG; Kontos CK; Adamopoulos PG; Nakou E; Vakalopoulou S; Garypidou V; Papaioannou M; Hatjiharissi E; Papadaki HA; Spanoudakis E; Pappa V; Scorilas A; Tsatalas C; Kotsianidis I; Clin Cancer Res; 2016 Apr; 22(8):1958-68. PubMed ID: 26700206 [TBL] [Abstract][Full Text] [Related]
11. CD34+ cells from patients with myelodysplastic syndrome present different p21 dependent premature senescence. Xiao Y; Wang J; Song H; Zou P; Zhou D; Liu L Leuk Res; 2013 Mar; 37(3):333-40. PubMed ID: 23219618 [TBL] [Abstract][Full Text] [Related]
12. Comparison of in vitro growth characteristics of blast cell progenitors (CFU-L) in patients with myelodysplastic syndromes and acute myeloid leukemia. Aul C; Gattermann N; Schneider W Blood; 1992 Aug; 80(3):625-33. PubMed ID: 1638020 [TBL] [Abstract][Full Text] [Related]
13. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy. Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic criteria for hypocellular acute leukemia: a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome. Nagai K; Kohno T; Chen YX; Tsushima H; Mori H; Nakamura H; Jinnai I; Matsuo T; Kuriyama K; Tomonaga M; Bennett JM Leuk Res; 1996 Jul; 20(7):563-74. PubMed ID: 8795690 [TBL] [Abstract][Full Text] [Related]
15. Iron overload promotes erythroid apoptosis through regulating HIF-1a/ROS signaling pathway in patients with myelodysplastic syndrome. Zheng QQ; Zhao YS; Guo J; Zhao SD; Song LX; Fei CM; Zhang Z; Li X; Chang CK Leuk Res; 2017 Jul; 58():55-62. PubMed ID: 28460338 [TBL] [Abstract][Full Text] [Related]
16. The effects of secondary iron overload and iron chelation on a radiation-induced acute myeloid leukemia mouse model. Chan LSA; Gu LC; Wells RA BMC Cancer; 2021 May; 21(1):509. PubMed ID: 33957868 [TBL] [Abstract][Full Text] [Related]
17. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry. Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836 [TBL] [Abstract][Full Text] [Related]
18. The impact of iron chelation therapy on patients with lower/intermediate IPSS MDS and the prognostic role of elevated serum ferritin in patients with MDS and AML: A meta-analysis. Yang Y; Tang Z; An T; Zhao L Medicine (Baltimore); 2019 Oct; 98(40):e17406. PubMed ID: 31577751 [TBL] [Abstract][Full Text] [Related]
19. Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy. Vaxevanis CK; Bauer M; Subbarayan K; Friedrich M; Massa C; Biehl K; Al-Ali HK; Wickenhauser C; Seliger B Oncoimmunology; 2023; 12(1):2152998. PubMed ID: 36531688 [TBL] [Abstract][Full Text] [Related]
20. Comparison of blast percentage calculated based on bone marrow all nucleated cells and non-erythroid cells in myelodysplastic syndromes with erythroid hyperplasia. Mashima K; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Umino K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Sugimoto M; Ishihara Y; Ashizawa M; Yamamoto C; Fujiwara SI; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y Ann Hematol; 2019 May; 98(5):1127-1133. PubMed ID: 30474718 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]